Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Tecan Group AG's Debt-to-EBITDA or its related term are showing as below:
LTS:0QLN'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -5.88 Med: 0.33 Max: 2.17
Current: -5.88
During the past 13 years, the highest Debt-to-EBITDA Ratio of Tecan Group AG was 2.17. The lowest was -5.88. And the median was 0.33.
LTS:0QLN's Debt-to-EBITDA is ranked worse than 100% of 467
companies
in the Medical Devices & Instruments industry
Industry Median: 1.6
vs LTS:0QLN: -5.88
Tecan Group AG (LTS:0QLN) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Tecan Group AG Debt-to-EBITDA Related Terms
Tecan Group AG Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Tecan Group AG's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0QLN vs ISRG, BDX, MDLN: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Tecan Group AG's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tecan Group AG Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tecan Group AG's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Tecan Group AG's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Tecan Group AG (LTS:0QLN) has a Debt-to-EBITDA of -1.17 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Tecan Group AG. According to the industry distribution chart, Tecan Group AG ranks #999999 out of 467 companies in the Medical Devices & Instruments industry.
Is Tecan Group AG's Debt-to-EBITDA too high?
Tecan Group AG's current Debt-to-EBITDA is -1.17. Based on the distribution chart, Tecan Group AG ranks #999999 out of 467 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Tecan Group AG has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tecan Group AG's Debt-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Tecan Group AG ranks #999999 out of 467 companies for Debt-to-EBITDA. This places Tecan Group AG in the lower half of its industry. The industry median Debt-to-EBITDA is 1.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.60, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Tecan Group AG. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tecan Group AG's current Debt-to-EBITDA is -1.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tecan Group AG stock overvalued right now?
Based on GuruFocus' analysis, Tecan Group AG (LTS:0QLN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF243.77, compared to a current price of CHF184.38 — trading 24.4% below its estimated fair value. The current Debt-to-EBITDA is -1.17. Tecan Group AG's overall GF Score™ is 77/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Tecan Group AG (LTS:0QLN), the current Debt-to-EBITDA is -1.17 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tecan Group AG (LTS:0QLN) Overvalued in 2026?
Based on GuruFocus' analysis, Tecan Group AG stock appears to be undervalued.
The current stock price of CHF184.38 is trading 24.4% below its estimated GF Value™ of CHF243.77.
GuruFocus considers Tecan Group AG to be Modestly Undervalued.
Key valuation signals for LTS:0QLN:
Debt-to-EBITDA: -1.17
GF Value™: CHF243.77 vs. price of CHF184.38 (24.4% below fair value)
No single metric tells the full story. See the LTS:0QLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tecan Group AG sells automated laboratory instruments and solutions for the diagnostics and life sciences research markets. The firm operates in two segments; The Life Sciences Business (end-customer business) segment supplies end users with automated workflow solutions directly. These solutions include laboratory instruments, software packages, application know-how, services, consumables, and spare parts, The partnering Business (OEM business) segment develops and manufactures OEM instruments and components that are distributed by partner companies under their names. A majority proportion of Tecan's revenue is generated in the Americas and Europe followed by Asia Specific.
77GF Score
Get the complete analysis for LTS:0QLN
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0QLN has been successfully added to your 
